Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Long-term Safety and Pharmacodynamics of GZ/SAR402671 in Adult Male Fabry Disease Patients
2014-004995-49Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venglustat in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Long-term safety profile of GZ/SAR402671. Started May 2015; status: completed.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2014-004995-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004995-49.